
AbbVie acquires psychedelic for major depressive disorder
AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead asset, bretisilocin (GM-2505), a potential best-in-class compound for the treatment of major depressive disorder (MDD), for up to $1.2 billion. Psychedelic compounds have gained recognition as potential treatments for mental health disorders, because of their demonstrated rapid, robust and… Read More














